1
Crown Bioscience and Medical & MBL, today announced the formation of a joint venture.
2
Crown Bioscience and Medical & MBL, today announced the formation of a joint venture.
Discover the infinite power of partnership to drive scientific discovery
Crown Bioscience is a Contract Research Organization (CRO) driven by our mission is to empower our customers to improve human health.
We do this by engaging the finest scientific talent, upholding the highest quality standards, and relentlessly pursuing innovation.
Every day we strive to accelerate and de-risk drug development to help realize a world where every patient gets the right treatment, at the right time.
It is well-known that drug attrition rates for anticancer agents are very high. In fact, only about 5% of compounds in preclinical development eventually becoming approved for clinical use. The need for more clinically relevant preclinical models has been identified as one of the areas that can reduce this attrition rate by enabling better decisions when selecting agents to advance to the clinic.
3D adult stem cell (ASC)-derived tumor organoids can enhance the translatability of drug discovery data, especially in combination with high content imaging (HCI). In this blog post, we explore how the pairing of these two technologies allows researchers to develop highly comprehensive and predictive data that can enable better decisions earlier in drug discovery, while improving the translatability of the most promising lead compounds.
This post explores applications of genetically engineered organoids and cell lines to expand and accelerate anti-cancer drug discovery and development. We first provide a brief overview of two major methods that are used to develop engineered organoids/cell lines (i.e., lentiviral transduction and PiggyBac), followed by typical workflows for generating these models. Several case studies are presented to showcase their application for target validation and in vitro /in vivo efficacy studies.
Drug development is a lengthy, risky, and costly endeavor with high candidate attrition. Attrition rates for anticancer agents are much higher than in other therapeutic categories. Only 5% of them are estimated to reach the clinical stage. This very high rate has been attributed in part to the poor translatability of current preclinical data.
